News

12 Aug 2025

SVN-SDN-14 PTSD - Positive pre-clinical results

12 Aug 2025

SVN-SDN-14 PTSD - Positive pre-clinical results

12 Aug 2025

SVN-SDN-14 PTSD - Positive pre-clinical results

12 Aug 2025

SVN-SDN-14 PTSD - Positive pre-clinical results

12 Aug 2025

SVN-SDN-14 PTSD - Positive pre-clinical results
Solvonis Therapeutics

11 Jul 2025

£1.0 million subscription by major shareholders to accelerate AI drug discovery programme
Solvonis Therapeutics

11 Jul 2025

£1.0 million subscription by major shareholders to accelerate AI drug discovery programme
Solvonis Therapeutics

11 Jul 2025

£1.0 million subscription by major shareholders to accelerate AI drug discovery programme
Solvonis Therapeutics

11 Jul 2025

£1.0 million subscription by major shareholders to accelerate AI drug discovery programme
Solvonis Therapeutics

11 Jul 2025

£1.0 million subscription by major shareholders to accelerate AI drug discovery programme
Solvonis Therapeutics

26 Jun 2025

Initiation of research coverage by Singer Capital Markets
Solvonis Therapeutics

26 Jun 2025

Initiation of research coverage by Singer Capital Markets
Solvonis Therapeutics

26 Jun 2025

Initiation of research coverage by Singer Capital Markets
Solvonis Therapeutics

26 Jun 2025

Initiation of research coverage by Singer Capital Markets
Solvonis Therapeutics

26 Jun 2025

Initiation of research coverage by Singer Capital Markets
Solvonis Therapeutics

23 Jun 2025

Allowance of U.S. patent covering AI-supported CNS discovery programme compounds
Solvonis Therapeutics

23 Jun 2025

Allowance of U.S. patent covering AI-supported CNS discovery programme compounds
Solvonis Therapeutics

23 Jun 2025

Allowance of U.S. patent covering AI-supported CNS discovery programme compounds
Solvonis Therapeutics

23 Jun 2025

Allowance of U.S. patent covering AI-supported CNS discovery programme compounds
Solvonis Therapeutics

23 Jun 2025

Allowance of U.S. patent covering AI-supported CNS discovery programme compounds
Solvonis Therapeutics

11 Jun 2025

Initiation of artificial intelligence-supported CNS drug discovery programme
Solvonis Therapeutics

11 Jun 2025

Initiation of artificial intelligence-supported CNS drug discovery programme
Solvonis Therapeutics

11 Jun 2025

Initiation of artificial intelligence-supported CNS drug discovery programme
Solvonis Therapeutics

11 Jun 2025

Initiation of artificial intelligence-supported CNS drug discovery programme
Solvonis Therapeutics

11 Jun 2025

Initiation of artificial intelligence-supported CNS drug discovery programme
Solvonis Therapeutics

27 May 2025

Completion of the acquisition of Awakn Life Sciences Corp
Solvonis Therapeutics

27 May 2025

Completion of the acquisition of Awakn Life Sciences Corp
Solvonis Therapeutics

27 May 2025

Completion of the acquisition of Awakn Life Sciences Corp
Solvonis Therapeutics

27 May 2025

Completion of the acquisition of Awakn Life Sciences Corp
Solvonis Therapeutics

27 May 2025

Completion of the acquisition of Awakn Life Sciences Corp
Dr Renata Crome

14 Mar 2025

Statement on the appointment Dr Renata Crome, Non-Executive Director.
Dr Renata Crome

14 Mar 2025

Statement on the appointment Dr Renata Crome, Non-Executive Director.
Dr Renata Crome

14 Mar 2025

Statement on the appointment Dr Renata Crome, Non-Executive Director.
Dr Renata Crome

14 Mar 2025

Statement on the appointment Dr Renata Crome, Non-Executive Director.
Dr Renata Crome

14 Mar 2025

Statement on the appointment Dr Renata Crome, Non-Executive Director.